Compare BLND & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | PCRX |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.7M | 1.0B |
| IPO Year | 2021 | 2011 |
| Metric | BLND | PCRX |
|---|---|---|
| Price | $3.37 | $24.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $4.80 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 4.3M | 647.6K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $167,532,000.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | $19.81 | $9.53 |
| P/E Ratio | ★ N/A | $52.56 |
| Revenue Growth | ★ 37.61 | 3.14 |
| 52 Week Low | $2.50 | $18.17 |
| 52 Week High | $5.41 | $27.64 |
| Indicator | BLND | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 62.04 |
| Support Level | $3.10 | $23.63 |
| Resistance Level | $3.23 | $24.81 |
| Average True Range (ATR) | 0.15 | 1.00 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 92.98 | 86.09 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.